BXQ-350, An Innovative Asset
With Potential For Multiple Indications

BXQ-350 is the foundation of our pipeline and has demonstrated activity in many different types of cancer mouse models, including glioblastoma and pancreatic cancer. Early clinical results have also shown a strong safety and tolerability profile. There is a critical need for new, safe and effective therapies in Oncology and Bexion is committed to progressing its development through a robust clinical trial program of our novel BXQ-350 franchise.